Irinotecan (CPT-11) combined with UFT as first line treatment of advanced colorectal carcinoma-A phase II study.

被引：0
|
作者：
Cohen, Y
Shulman, K
Idelevich, E
Ben-Shachar, M
Honnigman, J
Haiat, H
Zidan, J
Hubert, A
Kuten, A
Beny, A
机构：
[1] Soroka Med Ctr, Beer Sheva, Israel
[2] Rambam Med Ctr, Haifa, Israel
[3] Kaplan Med Ctr, Rehovot, Israel
[4] Nahariya Med Ctr, Nahariyya, Israel
[5] HaEmek Med Ctr, Afula, Israel
[6] Wolfson Med Ctr, Holon, Israel
[7] Ziv Med Ctr, Sefad, Israel
[8] Hadassah Med Ctr, IL-91120 Jerusalem, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3742
引用
收藏
页码：304S / 304S
页数：1
相关论文
共 50 条
  • [1] Irinotecan (CPT-11) as first line treatment of patients with not pretreated advanced colorectal cancer
    Firyida, JL
    Menendez, MD
    Mel, JR
    Diz, P
    Constenla-Figueiras, M
    Casal, J
    Valladares, M
    Castellanos, J
    Balcells, M
    ANNALS OF ONCOLOGY, 1998, 9 : 38 - 39
  • [2] Irinotecan (CPT-11) plus mitomycin C (MMC) for the second line treatment of patients (PTS) with advanced colorectal carcinoma (ACC). A phase I/II study.
    Casaretti, R
    Biglietto, M
    De Lucia, L
    De Cataldis, G
    Di Lullo, L
    Maiorino, L
    Avallone, A
    Guarrasi, R
    Comella, P
    Comella, G
    ANNALS OF ONCOLOGY, 2000, 11 : 65 - 65
  • [3] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    J. Cassinello
    P. López-Alvarez
    A. Martínez-Guisado
    M. Valladares
    G. Huidobro
    R. López
    U. Bohn
    I. Sevilla
    P. Ballesteros
    M. Jorge
    R. Pérez-Carrión
    J. L. Fernández
    J. Dorta
    Medical Oncology, 2003, 20 : 37 - 43
  • [4] Phase II study of weekly irinotecan (CPT-11) as second-line treatment of patients with advanced colorectal cancer
    Cassinello, J
    López-Alvarez, P
    Martínez-Guisado, A
    Valladares, M
    Huidobro, G
    López, R
    Bohn, U
    Sevilla, I
    Ballesteros, P
    Jorge, M
    Pérez-Carrión, R
    Fernández, JL
    Dorta, J
    MEDICAL ONCOLOGY, 2003, 20 (01) : 37 - 43
  • [5] Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Watanabe, M.
    Matsui, N.
    Kusano, M.
    ONCOLOGY, 2009, 77 (3-4) : 192 - 196
  • [6] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma
    Poon, D
    Chowbay, B
    Cheung, YB
    Leong, SS
    Tan, EH
    CANCER, 2005, 103 (03) : 576 - 581
  • [7] Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma (NPC).
    Poon, D
    Chowbay, B
    Leong, SS
    Cheung, YB
    Toh, CK
    Tay, MH
    Lim, WT
    Tan, EH
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 507S - 507S
  • [8] A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix
    Irvin, WP
    Price, FV
    Bailey, H
    Gelder, M
    Rosenbluth, R
    Durivage, HJ
    Potkul, RK
    CANCER, 1998, 82 (02) : 328 - 333
  • [9] First-line Treatment With Capecitabine Combined With Irinotecan in Patients With Advanced Colorectal Carcinoma A Phase II Study
    Assy, Nimer
    Basher, Walid
    Chetver, Lika
    Shnaider, Julia
    Zidan, Jamal
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2012, 46 (04) : E27 - E30
  • [10] Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer
    Tsunoda, A.
    Yasuda, N.
    Nakao, K.
    Narita, K.
    Yamazaki, K.
    Watanabe, M.
    Suzuki, N.
    Kusano, M.
    ONCOLOGY, 2007, 72 (1-2) : 58 - 63
12345